BNET Industries
Market Cap:$148.4B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Pfizer Raises Quarterly Dividend 13%, See More Annual Hikes
-
Pfizer lifts dividend, yield closer to rivals
-
BRIEF: SEC probing insider-trading allegations
-
Pfizer joins partnership with Calif. firm: Collaboration planned with Crown Bioscience for cancer research
-
Research and Markets: The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to...
-
Science and Technology: Pfizer to buy Croatian drug patent
-
Bristol-Myers Squibb Raises Exchange Offer Price For Mead Johnson Shares - Update
-
'IT boosts efficiency & innovation'
-
Inspector General Saved Billions in Healthcare This Year
-
Survey of Alberta nonprofits shows revenues continue to decline
-
Reportlinker Adds Growth Factors Blood And Tissue - A World Report
-
Market Report -- In Play PFE
-
Protalix Completes NDA Submission for taliglucerase alfa for the Treatment of Gaucher's Disease
-
Pfizer Inc. PFE JOBS Acquires Rights to Protalix Biotherapeutics's Gaucher Drug in Deal Worth $115M
-
Conservationists salute two corporations
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
2009: The Year That Was For Pfizer
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
News & Analysis
Filter by
agreement and pfizer inc. - All News and Analysis
Cardinal Health, Inc. F2Q09 (Qtr End 12/31/08) Earnings Call Transcript
Seeking Alpha
- 2009-02-05
Question-and-Answer Session Operator And your first question comes from the line of Lisa Gill of JPMorgan. Please proceed. Lisa Gill - JPMorgan Thanks very much and good morning. Thanks, George, for all the detail around the distribution component of the business, but I'm just wondering, can you maybe just...
Pfizer Cuts a Deal -- No Bid for Ranbaxy
BNET
- 2008-06-18
So Pfizer apparently won't be playing the spoiler in the Daiichi-Ranbaxy merger after all. Instead, CEO Jeff Kindler cut a deal with the Indian generics maker that will delay the introduction of generic Lipitor by about 20 months. Ranbaxy is now spared the cost and uncertainty involved...
pSivida Quarterly Cash Flow - March 31, 2008 Commentary and Highlights
- 2008-04-30
- Reincorporation Plan Announced - Medidur Collaboration Agreement Amended - BrachySil Pancreatic Cancer Phase IIa Results - Pfizer R&D Quarterly Payments Commence BOSTON, MA. & PERTH, Australia -- pSivida Limited (NASDAQ: PSDV)(ASX: PSD)(FSE: PSI) announced the filing of its Quarterly Cash Flow Statement for the quarter...
Pfizer Animal Health Enters into Agreement to Acquire Animal Health Products from Schering-Plough
- 2008-04-23
PARIS -- Pfizer Animal Health today announced that it has entered into an agreement to acquire multiple product franchises from Schering-Plough Corporation covering all major animal health species including cattle, swine, equine, and companion animal.
Pfizer and AVANT Enter into Licensing and Development Agreement for Novel Therapeutic Vaccine Candidate for Brain Cancer
- 2008-04-16
NEW YORK & NEEDHAM, Mass. -- Pfizer, Inc (NYSE: PFE) and AVANT Immunotherapeutics (Nasdaq: AVAN), acting through its wholly-owned subsidiary Celldex Therapeutics, Inc. today announced that they have entered into an agreement under which Pfizer will be granted an exclusive worldwide license to a therapeutic cancer vaccine candidate, CDX-110, in...
Pfizer and Scil Finalize Agreement for Novel Cartilage Growth Factor
- 2008-01-16
NEW YORK & MARTINSRIED, Germany -- Pfizer Inc (NYSE:PFE) and Scil Technology GmbH Scil have signed a licensing agreement for worldwide collaboration on Scil's cartilage specific growth factor CD-RAP. Under this agreement, Pfizer will obtain a worldwide exclusive license to develop and commercialize CD-RAP. In addition to receiving royalties on...
Pfizer and Taisho Finalize Agreement for Novel Schizophrenia Drug Candidate
- 2008-01-07
NEW YORK & TOKYO -- Pfizer Inc [Headquarter: New York, NY, USA, CEO: Jeffrey B. Kindler] (hereinafter, Pfizer) and Taisho Pharmaceutical Co., Ltd. [Headquarter: Toshima-ku, Tokyo, Japan, President: Akira Uehara] (hereinafter, Taisho) have signed a definitive agreement, which replaces the letter of intent previously signed between the companies, for worldwide...
Pfizer and Nektar Reach Agreement on Exubera®
- 2007-11-13
NEW YORK & SAN CARLOS, Calif. -- Pfizer Inc (NYSE: PFE) and Nektar Therapeutics (NASDAQ: NKTR) announced today that the two companies have resolved all outstanding contractual issues in connection with Exubera[R] and Nektar's innovative Next Generation Inhaled Insulin NGI product currently in Phase 1 clinical development.
Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
- 2007-08-27
Companies Will Jointly Conduct Phase III Development and Commercialization of DGAT-1 Inhibitor Compounds
Pfizer and Express Scripts Sign Agreement
- 2007-05-30
ST. LOUIS & NEW YORK -- Express Scripts, Inc. (NASDAQ: ESRX), and Pfizer Inc (NYSE: PFE), today announced an agreement providing for Pfizer's participation in Express Scripts' rebate program. Due to improved terms under the agreement, Express Scripts has added Lipitor([R]) atorvastatin calcium, Pfizer's treatment for high cholesterol and the...
Industry Transcripts by Seeking Alpha
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
Presented by American Express